Nasal sprays for treating COVID-19: a scientific note

Area of Science:

• Immunology
• Virology
• Pharmacology

Background:

• COVID-19 management remains challenging due to limited specific treatments.
• Traditional vaccine and therapy delivery routes face logistical and patient compliance hurdles.
• The upper respiratory tract is the primary invasion site for SARS-CoV-2, highlighting the need for localized interventions.

Purpose of the Study:

• To explore the potential of nasal sprays for COVID-19 prophylaxis and therapy.
• To review the advantages of the nasal route for drug delivery compared to conventional methods.
• To discuss the development and application of nasal vaccines and therapies for SARS-CoV-2.

Main Methods:

• Review of current research on mucosal immunity and SARS-CoV-2.
• Analysis of the benefits of nasal drug delivery systems.
• Examination of the status of nasal vaccine development for COVID-19.

Main Results:

• Nasal vaccines are in development, targeting the initial site of SARS-CoV-2 infection.
• The nasal route provides needle-free, self-administered delivery with reduced logistical burdens (e.g., no refrigeration).
• Mucosal immunity can be harnessed for both prophylactic and therapeutic applications against COVID-19.

Conclusions:

• Nasal spray delivery presents a promising alternative for COVID-19 management.
• Exploiting mucosal immunity via the nasal route offers significant advantages for combating SARS-CoV-2.
• Further development of nasal sprays could revolutionize COVID-19 prevention and treatment strategies.